21-hydroxylase deficiency classification: Difference between revisions
Aditya Ganti (talk | contribs) |
|||
(35 intermediate revisions by 6 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{ | {{21-hydroxylase deficiency}} | ||
{{CMG}}; '''Associate Editor-In-Chief:''' {{ | {{CMG}}; '''Associate Editor-In-Chief:''' {{MJ}}, {{AAM}} | ||
==Overview== | ==Overview== | ||
21-hydroxylase deficiency may be classified according to the severity of disease and time of onset into two forms, classic and non-classic. The classic form can be sub-divided into two sub-types, which are salt-wasting and non-salt wasting 21-hydroxylase deficiency. | |||
==Classification== | ==Classification== | ||
21-hydroxylase deficiency my be classified by clinical manifestations in to two forms: | |||
*Classical form, most severe form of 21-hydroxylase deficiency, presents during the [[neonatal]] period and early [[infancy]]. The classic form can be classified in to two subtypes based on [[aldosterone]] status: | |||
**Classic salt wasting, [[aldosterone]] deficient. | |||
**Classic non-salt wasting, normal [[aldosterone]]. | |||
*Non-classic form or late-onset 21-hydroxylase deficiency, presents later during the [[adolescence]] period.<ref name="pmid10857554">{{cite journal |vauthors=White PC, Speiser PW |title=Congenital adrenal hyperplasia due to 21-hydroxylase deficiency |journal=Endocr. Rev. |volume=21 |issue=3 |pages=245–91 |year=2000 |pmid=10857554 |doi=10.1210/edrv.21.3.0398 |url=}}</ref><ref name="pmid20823466">{{cite journal |vauthors=Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC |title=Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline |journal=J. Clin. Endocrinol. Metab. |volume=95 |issue=9 |pages=4133–60 |year=2010 |pmid=20823466 |pmc=2936060 |doi=10.1210/jc.2009-2631 |url=}}</ref> | |||
=== | == References == | ||
{{Reflist|2}} | |||
{{WS}} | |||
{{WH}} | |||
[[Category:Disease]] | [[Category:Disease]] | ||
[[Category:Pediatrics]] | [[Category:Pediatrics]] | ||
Line 28: | Line 23: | ||
[[Category:Genetic disorders]] | [[Category:Genetic disorders]] | ||
[[Category:Intersexuality]] | [[Category:Intersexuality]] | ||
[[Category:Medicine]] | |||
[[Category:Up-To-Date]] | |||
|
Latest revision as of 15:40, 24 July 2020
21-hydroxylase deficiency Microchapters |
Differentiating 21-Hydroxylase Deficiency from other Diseases |
Diagnosis |
Treatment |
Case Studies |
21-hydroxylase deficiency classification On the Web |
American Roentgen Ray Society Images of 21-hydroxylase deficiency classification |
Risk calculators and risk factors for 21-hydroxylase deficiency classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor-In-Chief: Mehrian Jafarizade, M.D [2], Ahmad Al Maradni, M.D. [3]
Overview
21-hydroxylase deficiency may be classified according to the severity of disease and time of onset into two forms, classic and non-classic. The classic form can be sub-divided into two sub-types, which are salt-wasting and non-salt wasting 21-hydroxylase deficiency.
Classification
21-hydroxylase deficiency my be classified by clinical manifestations in to two forms:
- Classical form, most severe form of 21-hydroxylase deficiency, presents during the neonatal period and early infancy. The classic form can be classified in to two subtypes based on aldosterone status:
- Classic salt wasting, aldosterone deficient.
- Classic non-salt wasting, normal aldosterone.
- Non-classic form or late-onset 21-hydroxylase deficiency, presents later during the adolescence period.[1][2]
References
- ↑ White PC, Speiser PW (2000). "Congenital adrenal hyperplasia due to 21-hydroxylase deficiency". Endocr. Rev. 21 (3): 245–91. doi:10.1210/edrv.21.3.0398. PMID 10857554.
- ↑ Speiser PW, Azziz R, Baskin LS, Ghizzoni L, Hensle TW, Merke DP, Meyer-Bahlburg HF, Miller WL, Montori VM, Oberfield SE, Ritzen M, White PC (2010). "Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline". J. Clin. Endocrinol. Metab. 95 (9): 4133–60. doi:10.1210/jc.2009-2631. PMC 2936060. PMID 20823466.